GlaxoSmithKline has announced an initiative to evaluate a new lower global warming potential propellant for its metered dose inhalers as part of an effort to reach net zero carbon emissions. According to GSK, its Ventolin albuterol (salbutamol) MDIs for the rescue treatment of asthma account for 45% of the company's current carbon emissions, and the company expects … [Read more...] about GSK says it is evaluating new MDI propellant as part of commitment to reducing greenhouse gas emissions
Business
Virpax to develop intranasal CBD for the treatment of epilepsy
Virpax says that it has acquired exclusive worldwide rights to Nanomerics's molecular envelope technology (MET) for use with Virpax's VRP324 intranasal dry powder cannabidiol (CBD) for the treatment of epilepsy. According to Virpax, Nanomerics is currently conducting preclinical studies of VRP324, which Virpax plans to develop for the treatment of seizures due to … [Read more...] about Virpax to develop intranasal CBD for the treatment of epilepsy
DDL, BTS announce that they will cut ties with Vectura following PMI acquisition
The Drug Delivery to the Lungs conference organizing committee and the British Thoracic Society have both announced that they will cut ties with inhalation CDMO Vectura following the company's acquisition by tobacco company Philip Morris International. Vectura announced in May 2021 that it would be acquired by the Carlyle Group; however, the company withdrew its … [Read more...] about DDL, BTS announce that they will cut ties with Vectura following PMI acquisition
Intravacc to offer intranasal vaccine contract development services
Dutch vaccine developer Intravacc has announced that it will continue to develop its pipeline of intranasal vaccines while adding a contract development and manufacturing business. The company said that it will offer GMP manufacturing for clinical trials in addition to R&D services and expects to take on one or two contract projects per year. Intravacc's pipeline … [Read more...] about Intravacc to offer intranasal vaccine contract development services
Theravance Biopharma restructures, will focus on respiratory drugs
Theravance Biopharma said that it expects to cut 270 jobs, or 75% of its current workforce, by February 2022 and that it will stop development of candidates outside of its respiratory portfolio. The announcement came just after the company announced the failure of a Phase 3 trial of its oral ampreloxetine. The company said that its R&D focus will now be on a label … [Read more...] about Theravance Biopharma restructures, will focus on respiratory drugs
ARS raises $55 million for potential launch of its Neffy intranasal epinephrine
ARS Pharmaceuticals said that it has raised $55 million in a Series D financing round to support approval and potential launch of its Neffy (ARS-1) intranasal epinephrine for the treatment of anaphylaxis as well as studies of the nasal spray for other indications. ARS submitted an MAA for Neffy to the EMA in November 2020. The FDA granted Fast Track designation … [Read more...] about ARS raises $55 million for potential launch of its Neffy intranasal epinephrine
Vivera gets US patents for Zicoh smart inhaler
Within one week in August, Vivera Pharmaceuticals has announced the issuance of two US patents covering its Zicoh smart inhaler technology. The first is US Patent No. 11,083,850 ("Secure smart dosing system with automated delivery, measurement, and management") and the second is US Patent No. 11,090,449 ("Smart inhaler device with automated dose delivery, measurement, … [Read more...] about Vivera gets US patents for Zicoh smart inhaler
Lupin launches Luforbec beclometasone/formoterol MDI in the UK
Lupin Healthcare has announced the launch of the Luforbec beclometasone/formoterol MDI in the UK. The generic version of Chiesi’s Fostair MDI was approved by the MHRA for the treatment of asthma and COPD in June 2021. According to Lupin, the Luforbec inhaler will be manufactured at the company's facilities in the US and India. The company cited UK prescribing data … [Read more...] about Lupin launches Luforbec beclometasone/formoterol MDI in the UK
Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx's SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19. The project is supported by Swiss life sciences investment company ADYA Consulting. According to the … [Read more...] about Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Cellics partners with HCmed on delivery of inhaled nanosponges
Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and the company expects to advance its CTI-005 RBC nanosponge into clinical development for the … [Read more...] about Cellics partners with HCmed on delivery of inhaled nanosponges